Gemcitabine in combination with EGF-receptor antibody (Cetuximab) as a treatment of cholangiocarcinoma: A case report

BMC Cancer

Volumn 6, Issue , 2006, Pages

  Sprinzl, Martin F ^a   Schimanski, Carl C ^a   Moehler, Markus ^a   Schadmand Fischer, Simin ^a   Galle, Peter R ^a   Kanzler, Stephan ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CONTRAST MEDIUM; EPITHELIAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GROWTH FACTOR RECEPTOR; PIPERACILLIN PLUS TAZOBACTAM; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

AGED; ALOPECIA; ANAMNESIS; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CASE REPORT; CATHETER INFECTION; CHOLANGITIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LAPAROSCOPY; LEUKOPENIA; LIVER BIOPSY; LIVER METASTASIS; MALE; NAUSEA; NEUTROPENIA; PERITONEAL BIOPSY; PERITONEUM CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; ROSACEA; SEPSIS; SKIN TOXICITY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BILE DUCT NEOPLASMS; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; HUMANS; LIVER NEOPLASMS; MALE; PALLIATIVE CARE; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 33748680142     PISSN: 14712407     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-6-190     Document Type: Article

References (18)

1. Mittal B, Deutsch M, Iwatsuki S: Primary cancers of extrahepatic biliary passages. Int J Radiat Oncol Biol Phys 1985, 11(4):849-854.
2. Kelley ST, Bloomston M, Serafini F, Carey LC, Karl RC, Zervos E, Goldin S, Rosemurgy P, Rosemurgy AS: Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004, 70(9):743-8; discussion 748-9.
3. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multi-center prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95(8):1685-1695.
4. Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and billary cancer. Ann Oncol 1996, 7(6):593-600.
5. Thongprasert S: The role of chemotherapy in cholangiocarcinoma. Ann Oncol 2005, 16 Suppl 2:ii93-6.
6. Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL: Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer. a multicenter phase II Trial. J Clin Oncol 2004, 22(13):2610-2616.
7. Loy TS, Calaluce RD: Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas. Am J Clin Pathol 1994, 102(6):764-767.
8. Tot T: Adenocarcinomas metastatic to the liver: the value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999, 85(1):171-177.
9. Normanno N, De Luca A. Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene In Press, Corrected Proof:.
10. Yoon JH, Gwak GY, Lee HS, Bronk SF, Werneburg NW, Gores GJ: Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells. J Hepatol 2004, 41(5):808-814.
11. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M: Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993, 13(3):565-569.
12. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983, 1(5):511-529.
13. Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, McLeod C, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth factor binding and antagonists of epidermal growth factor binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 1984, 259(12):7755-7760.
14. Goldman CK, Kim J, Wong WL, King V, Brock T, Gillespie GY: Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993, 4(1):121-133.
15. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351(4):337-345.
16. Saltz LB, Meropol NJ, Loehrer PJS, Needle MN, Kopit J, Mayer RJ: Phase II trial of cetuximab in patients with refractory colorectai cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004, 22(7):1201-1208.
17. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005, 23(9):1803-1810.
18. Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, Vokes EE: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003, 21(10):1980-1987.